Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
   Google Scholar   
Citation:
Leuk. Lymphoma vol 50 (10) 1589-96
Year:
2009
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Book Volume:
Parents:
470  
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
CA31946  
Corr. Author:
 
Authors:
                   
Study
CALGB-19901
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Adult, Aged, Alemtuzumab, Anti-Infective Agents, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm, Antigens, CD, Antigens, Neoplasm, Bone Marrow Diseases, CD52 Antigen, Cohort Studies, Cytomegalovirus Infections, Feasibility Studies, Female, Glycoproteins, Humans, Hypotension, Infusions, Intravenous, Injections, Subcutaneous, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neoplasm Proteins, Survival Analysis, Vidarabine